In phase 1, first‐in‐human, dose‐escalation study in heavily pre‐treated patients with CML‐CP, asciminib (10–200 mg once daily [qd] or twice daily [bid]) showed clinically meaningful efficacy, including a major molecular response rate (MMR; BCR::ABL1 transcript levels on the international scale [BCR::ABL1IS] ≤0.1%) by 12 months of 48% (44 of 91 evaluable patients), and a favorable safety and tolerability profile.22 This evidence concerns the gene CP and chronic myelogenous leukemia, BCR-ABL1 positive.